E-Mail
IMAGE: Sara Mangso is an Associate senior lecturer/Assistant Professor at the Department of Pharmaceutical Biosciences, Uppsala University view more
Credit: Mikael Wallerstedt
In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
Immunotherapy - utilising the body s own immune system to combat tumour cells - is an area in which rapid progress is being made. Many new treatments are helping to increase survival rates among cancer patients, but more effective tools are still needed to predict how these drugs will affect an individual s immune system. In a new study at Uppsala University, researchers compared what happens when Rituximab monoclonal an
New analysis method could pave the way for important breakthroughs in immunotherapy
In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
Immunotherapy - utilizing the body s own immune system to combat tumor cells - is an area in which rapid progress is being made. Many new treatments are helping to increase survival rates among cancer patients, but more effective tools are still needed to predict how these drugs will affect an individual s immune system. In a new study at Uppsala University, researchers compared what happens when Rituximab monoclonal antibodies interact with the blood of healthy individuals and of patients with the disease that the monoclonal antibodie